Expert consensus on immune checkpoint inhibitors treatment for recurrent/metastatic head and neck squamous cell carcinoma (2024 edition)

Ye GUO; Chenping ZHANG

doi:10.19401/j.cnki.1007-3639.2024.04.010

您当前的位置：

首页 >

文章列表页 >

Expert consensus on immune checkpoint inhibitors treatment for recurrent/metastatic head and neck squamous cell carcinoma (2024 edition)

Guideline and Concensus | 更新时间：2025-12-31

- Expert consensus on immune checkpoint inhibitors treatment for recurrent/metastatic head and neck squamous cell carcinoma (2024 edition)
- China Oncology Vol. 34, Issue 4, Pages: 425-438(2024)
- 作者机构：
  
  1. 中国临床肿瘤学会头颈肿瘤专家委员会
  2. 中国抗癌协会头颈肿瘤专业委员会
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.04.010
  CLC： R730.51
- Received：31 May 2023，
  
  Revised：2023-10-04，
  
  Published：30 April 2024
- 稿件说明：
移动端阅览
Ye GUO, Chenping ZHANG. Expert consensus on immune checkpoint inhibitors treatment for recurrent/metastatic head and neck squamous cell carcinoma (2024 edition)[J]. China Oncology, 2024, 34(4): 425-438.
DOI：

Ye GUO, Chenping ZHANG. Expert consensus on immune checkpoint inhibitors treatment for recurrent/metastatic head and neck squamous cell carcinoma (2024 edition)[J]. China Oncology, 2024, 34(4): 425-438. DOI： 10.19401/j.cnki.1007-3639.2024.04.010.

摘要

头颈部鳞状细胞癌（head and neck squamous cell carcinoma，HNSCC）是头颈部肿瘤最为常见的一种类型，具有较高的发病率和死亡率。随着帕博利珠单抗和纳武利尤单抗在国内相继获批用于复发/转移性（recurrent/metastatic，R/M）HNSCC的一线及后线治疗，免疫治疗已然成为R/M HNSCC的标准治疗。随着免疫检查点抑制剂（immune checkpoint inhibitor，ICI）在临床中的广泛应用，生物标志物检测、不同人群免疫治疗方案的选择、免疫治疗效果的评估、免疫治疗不良反应（immunotherapy-related adverse event，irAE）的处理等也在不断规范和完善。中国临床肿瘤学会（Chinese Society of Clinical Oncology，CSCO）头颈肿瘤专家委员会和中国抗癌协会（China Anti-Cancer Association，CACA）头颈肿瘤专业委员会组织专家组进行深入探讨，共同制定了《复发/转移性头颈部鳞癌免疫检查点抑制剂治疗专家共识》，旨在形成相对规范统一的认识，更好地指导临床实践。经过多轮商议和探讨，专家组汇总出以下推荐意见。程序性死亡受体-配体1（programmed death-ligand 1，PD-L1）表达是抗程序性死亡受体1（programmed death-1，PD-1）单抗一线治疗R/M HNSCC的疗效预测生物标志物，推荐患者治疗前常规进行PD-L1联合阳性评分（combined positive score，CPS）检测。对于PD-L1 CPS≥1的患者，推荐帕博利珠单抗联合铂类药物和5-FU，或者帕博利珠单抗单药作为一线治疗方案。关于帕博利珠单抗单药或联合化疗方案的选择，需结合患者的PD-L1 CPS评分（如CPS评分是否≥20）、肿瘤负荷或临床症状进行综合判断。对于PD-L1表达情况未知或PD-L1 CPS<1的患者，可选择帕博利珠单抗联合铂类药物和5-FU作为一线治疗方案。对于不适合使用5-FU的患者，可选择帕博利珠单抗联合铂类药物和紫杉类药物作为一线治疗方案。对于铂类药物耐药或复发/转移阶段含铂类药物治疗失败且既往未接受过抗PD-1单抗治疗的患者，推荐纳武利尤单抗或帕博利珠单抗作为后线治疗。对于无法耐受化疗且不适合接受抗PD-1单抗单药治疗的患者，可选择帕博利珠单抗或纳武利尤单抗联合西妥昔单抗作为一线或后线治疗方案。对于接受ICI的患者，推荐在治疗全程密切监测免疫相关不良反应的症状并及时作出判断，必要时进行多学科联合诊治。

Abstract

Head and neck squamous cell carcinoma (HNSCC) is the most common head and neck tumor

characterized by high morbidity and high mortality. Since pembrolizumab and nivolumab were approved for the first line and platinum-refractory disease treatment of HNSCC

immunotherapy has become the standard of care for recurrent/metastatic (R/M) HNSCC. With the wide clinical application of immune checkpoint inhibitors

clinical guidance is needed on the use of these agents

including biomarker testing

appropriate patient selection

response assessment and adverse event management. To better guide the clinical treatment of R/M HNSCC patients on immune checkpoint inhibitors

the Chinese Society of Clinical Oncology (CSCO) and the China Anti-Cancer Association (CACA) convened an expert task force charged with developing consensus recommendations on these key aspects. This consensus serves as a guidance to standardize utilization of immunotherapy in HNSCC and to optimize clinical practice. After several rounds of discussion

the expert task force generated the following consensus recommendations. Programmed death-ligand 1 (PD-L1) expression is a predictive biomarker of anti-programmed death-1 (PD-1) first-line therapy for R/M HNSCC patients. It is recommended to routinely perform PD-L1 combined positive score (CPS) testing in patients before treatment. Pembrolizumab monotherapy or pembrolizumab in combination with platinum and 5-FU is recommended as first-line treatment for R/M HNSCC patients with PD-L1 CPS≥1. There is a need for a comprehensive consideration of PD-L1 CPS score (e.g.

if CPS≥20)

tumor burden and clinical symptoms when those patients are treated with pembrolizumab monotherapy or pembrolizumab combination regimen. Pembrolizumab in combination with platinum and 5-FU could be the first-line treatment option for R/M HNSCC patients with PD-L1 unknown or PD-L1 CPS<1. Pembrolizumab in combination with platinum and taxane could be the first-line treatment option for patients who are intolerant of 5-FU. Nivolumab or pembrolizumab is recommended as the late-line treatment for platinum-resistant patients or patients who are platinum-refractory and have not previously received PD-1 inhibitors in R/M setting. For patients who are intolerant of chemotherapy and unsuitable for PD-1 inhibitor monotherapy

pembrolizumab or nivolumab in combination with cetuximab can be the treatment option as first-line or late-line therapy. For patients treated with immune checkpoint inhibitors

it is recommended to closely monitor the signs of adverse events during the whole course of treatment and use the multidisciplinary team (MDT) for treatment strategy if necessary.

关键词

Keywords

references

SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 .

ZHENG R S , ZHANG S W , ZENG H M , et al . Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Cent , 2022 , 2 ( 1 ): 1 - 9 .

FORASTIERE A A , METCH B , SCHULLER D E , et al . Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study [J ] . J Clin Oncol , 1992 , 10 ( 8 ): 1245 - 1251 . DOI: 10.1200/JCO.1992.10.8.1245 http://doi.org/10.1200/JCO.1992.10.8.1245

GIBSON M K , LI Y , MURPHY B , et al . Randomized phase Ⅲ evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group [J ] . J Clin Oncol , 2005 , 23 ( 15 ): 3562 - 3567 .

VERMORKEN J B , MESIA R , RIVERA F , et al . Platinum-based chemotherapy plus cetuximab in head and neck cancer [J ] . N Engl J Med , 2008 , 359 ( 11 ): 1116 - 1127 .

TAHARA M , GREIL R , RISCHIN D , et al . 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048 [J ] . Ann Oncol , 2022 , 33 : S844 .

Nuffield Department of Primary Care Health Sciences . Oxford Centre for Evidence-Based Medicine: levels of evidence (March 2009 ) [EB/OL ] . [2023-08-10 ] . https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009

FINK A , KOSECOFF J , CHASSIN M , et al . Consensus methods: characteristics and guidelines for use [J ] . Am J Public Health , 1984 , 74 ( 9 ): 979 - 983 . DOI: 10.2105/ajph.74.9.979 http://doi.org/10.2105/ajph.74.9.979

European Society for Medical Oncology . ESMO guidelines methodology [EB/OL ] . [2023-10-04 ] . http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology

FERRIS R L . Immunology and immunotherapy of head and neck cancer [J ] . J Clin Oncol , 2015 , 33 ( 29 ): 3293 - 3304 . DOI: 10.1200/JCO.2015.61.1509 http://doi.org/10.1200/JCO.2015.61.1509

GONG J , CHEHRAZI-RAFFLE A , REDDI S , et al . Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations [J ] . J Immunother Cancer , 2018 , 6 ( 1 ): 8 . DOI: 10.1186/s40425-018-0316-z http://doi.org/10.1186/s40425-018-0316-z

DE RUITER E J , MULDER F J , KOOMEN B M , et al . Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC) [J ] . Mod Pathol , 2021 , 34 ( 6 ): 1125 - 1132 .

FERRIS R L , BLUMENSCHEIN G Jr , FAYETTE J , et al . Nivolumab for recurrent squamous-cell carcinoma of the head and neck [J ] . N Engl J Med , 2016 , 375 ( 19 ): 1856 - 1867 .

COHEN E E W , SOULIÈRES D , TOURNEAU C L , et al . Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study [J ] . Lancet , 2019 , 393 ( 10167 ): 156 - 167 . DOI: S0140-6736(18)31999-8 http://doi.org/S0140-6736(18)31999-8

CHOW L Q M , HADDAD R , GUPTA S , et al . Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ⅰb KEYNOTE-012 expansion cohort [J ] . J Clin Oncol , 2016 , 34 ( 32 ): 3838 - 3845 .

BAUML J , SEIWERT T Y , PFISTER D G , et al . Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase Ⅱ study [J ] . J Clin Oncol , 2017 , 35 ( 14 ): 1542 - 1549 .

EMANCIPATOR K , HUANG L K , AURORA-GARG D , et al . Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer [J ] . Mod Pathol , 2021 , 34 ( 3 ): 532 - 541 .

BURTNESS B , HARRINGTON K J , GREIL R , et al . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J ] . Lancet , 2019 , 394 ( 10212 ): 1915 - 1928 . DOI: S0140-6736(19)32591-7 http://doi.org/S0140-6736(19)32591-7

YILMAZ E , ISMAILA N , BAUMAN J E , et al . Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO guideline [J ] . J Clin Oncol , 2023 , 41 ( 5 ): 1132 - 1146 .

国家药品监督管理局 . phNMPA 批准PD-L1检测试剂盒(免疫组织化学法)PD-L1 IHC 22C3 pharmDx用于定性检测头颈部鳞状细胞癌(HNSCC)组织中的PD-L1蛋白,用作KEYTRUDA ® 的伴随诊断 [EB/OL ] . [2022-10-31 ] . https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz. https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz

National Medical Products Administration . NMPA approves PD-L1 IHC 22C3 pharmDx for qualitative detection of PD-L1 protein in head and neck squamous cell carcinoma (HNSCC) tissue as a companion diagnostic for KEYTRUDA® [EB/OL ] . [2022-10-31 ] . https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz. https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGE4ODdiZjQ2NDU4NzE2MDAxNjQ4YzcxZDM1YzI3N2MmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz

LU H Z , KUANG D , JIANG L L , et al . The PD-L1 protein expression in Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma: a multi-center retrospective study [J ] . Cancer Res , 2023 , 83 ( 7_Suppl ): 5463 .

辇伟奇 , 聂勇战 , 应建明 , 等 . 肿瘤突变负荷检测及临床应用中国专家共识(2020年版) [J ] . 中国癌症防治杂志 , 2020 , 12 ( 5 ): 485 - 494 .

NIAN W Q , NIE Y Z , YING J M , et al . Chinese expert consensus on tumor mutational burden testing and clinical application [J ] . Chin J Oncol Prev Treat , 2020 , 12 ( 5 ): 485 - 494 .

SCHUMACHER T N , SCHREIBER R D . Neoantigens in cancer immunotherapy [J ] . Science , 2015 , 348 ( 6230 ): 69 - 74 . DOI: 10.1126/science.aaa4971 http://doi.org/10.1126/science.aaa4971

CHALMERS Z R , CONNELLY C F , FABRIZIO D , et al . Analysis of 100 000 human cancer genomes reveals the landscape of tumor mutational burden [J ] . Genome Med , 2017 , 9 ( 1 ): 34 .

MARABELLE A , FAKIH M , LOPEZ J , et al . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study [J ] . Lancet Oncol , 2020 , 21 ( 10 ): 1353 - 1365 . DOI: S1470-2045(20)30445-9 http://doi.org/S1470-2045(20)30445-9

U.S. FOOD & DRUG ADMINISTRATION . FDA approves pembrolizumab for adults and children with TMB-H solid tumors [EB/OL ] . [2020-06-16 ] . https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors

HADDAD R I , SEIWERT T Y , CHOW L Q M , et al . Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma [J ] . J Immunother Cancer , 2022 , 10 ( 2 ): e003026 .

National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN guidelines ® ) for head and neck cancer.Version 1. 2023 [EB/OL ] . [2022-12-20 ] . https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf

NGAMPHAIBOON N , TANAKA K , HONG R L , et al . Phase Ⅲ KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis [J ] . Ann Oncol , 2019 , 30 : ix97 .

默沙东中国投资有限公司 . 帕博利珠单抗注射液说明书 [Z/OL ] . [2022-11-01 ] . https://www.msdchina.com.cn/product#p1A. https://www.msdchina.com.cn/product#p1A https://www.msdchina.com.cn/product#p1A

Merck Sharp & Dohme China Investment Co., Ltd . Package insert of pembrolizumab injection [Z/OL ] . [2022-11-01 ] . https://www.msdchina.com.cn/product#p1A. https://www.msdchina.com.cn/product#p1A https://www.msdchina.com.cn/product#p1A

中国临床肿瘤学会指南工作委员会组织 . 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南-2023 [M ] . 北京 : 人民卫生出版社 , 2023 .

Organized by the Guidelines Working Committee of the Chinese Society of Clinical Oncology . Chinese Society of Clinical Oncology (CSCO) guidelines for diagnosis and treatment of head and neck tumors-2023 [M ] . Beijing : People's Health Publishing House , 2023 .

KEAM B , MACHIELS J P , KIM H R , et al . Pan-Asian adaptation of the EHNS-ESMO-ESTRO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck [J ] . ESMO Open , 2021 , 6 ( 6 ): 100309 .

DZIENIS M R , CUNDOM J E , FUENTES C S , et al . Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): phase Ⅵ KEYNOTE-B10 study [J ] . Ann Oncol , 2022 , 33 ( S7 ): S839 - S840 .

GUI L , HE X , YANG J , et al . Pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: a prospective phase Ⅱ study [J ] . Ann Oncol , 2022 , 33 ( S7 ): S855 - S856 .

BLACK C , WANG L Y , RAMAKRISHNAN K , et al . Real-world overall survival among patients receiving first-line (1L) pembrolizumab in the treatment of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States [J ] . J ImmunoTher Cancer , 2022 , 10 ( S2 ): A830 - A830 .

BLACK C , WANG L Y , RAMAKRISHNAN K , et al . Real-world use of pembrolizumab combination regimens in first-line recurrent/metastatic head and neck squamous cell carcinoma [C ] // Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd , 2022 .

SEIWERT T Y , BURTNESS B , MEHRA R , et al . Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial [J ] . Lancet Oncol , 2016 , 17 ( 7 ): 956 - 965 . DOI: S1470-2045(16)30066-3 http://doi.org/S1470-2045(16)30066-3

U.S. FOOD & DRUG ADMINISTRATION . FDA approves pembrolizumab for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy [EB/OL ] . [2016-08-05 ] . https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda

SOULIERES D , HARRINGTON K J , LE TOURNEAU C , et al . Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040 [C ] . ESMO , 2022 , Abstract No. 658MO.

COHEN E E , SOULIÈRES D , LE TOURNEAU C , et al . Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040 [C ] . ASCO , 2018 , Abstract No. 6013.

U.S. FOOD & DRUG ADMINISTRATION . FDA approves nivolumab for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy [EB/OL ] . [2016-11-10 ] . https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn

HADDAD R I , HARRINGTON K , TAHARA M , et al . Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: The final results of CheckMate 651 [J ] . J Clin Oncol , 2023 , 41 ( 12 ): 2166 - 2180 .

PSYRRI A , FAYETTE J , HARRINGTON K , et al . Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase Ⅲ study [J ] . Ann Oncol , 2023 , 34 ( 3 ): 262 - 274 .

SACCO A G , CHEN R F , WORDEN F P , et al . Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial [J ] . Lancet Oncol , 2021 , 22 ( 6 ): 883 - 892 . DOI: 10.1016/S1470-2045(21)00136-4 http://doi.org/10.1016/S1470-2045(21)00136-4

CHUNG C H , LI J N , STEUER C E , et al . Phase Ⅱ multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma [J ] . Clin Cancer Res , 2022 , 28 ( 11 ): 2329 - 2338 .

KAO H F , LIAO B C , HUANG Y L , et al . Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA study): a phase Ⅱ study with biomarker analysis [J ] . Clin Cancer Res , 2022 , 28 ( 8 ): 1560 - 1571 .

SABA N F , STEUER C E , EKPENYONG A , et al . Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial [J ] . Nat Med , 2023 , 29 ( 4 ): 880 - 887 . DOI: 10.1038/s41591-023-02275-x http://doi.org/10.1038/s41591-023-02275-x

TAYLOR M H , LEE C H , MAKKER V , et al . Phase ⅠB/Ⅱ trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors [J ] . J Clin Oncol , 2020 , 38 ( 11 ): 1154 - 1163 .

SIU L L , BURTNESS B , COHEN E E W , et al . Phase Ⅲ LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) [J ] . J Clin Oncol , 2020 , 38 ( 15_suppl ): TPS6589 .

HARRINGTON K J , BURTNESS B , GREIL R , et al . Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase Ⅲ KEYNOTE-048 study [J ] . J Clin Oncol , 2023 , 41 ( 4 ): 790 - 802 .

SABA N F , BLUMENSCHEIN G Jr , GUIGAY J , et al . Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by age [J ] . Oral Oncol , 2019 , 96 : 7 - 14 .

SØBY S , GOTHELF A , GYLDENKERNE N , et al . Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study [J ] . Acta Oncol , 2022 , 61 ( 8 ): 972 - 978 . DOI: 10.1080/0284186X.2022.2103387 http://doi.org/10.1080/0284186X.2022.2103387

SALEH K , AUPERIN A , MARTIN N , et al . Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck [J ] . Eur J Cancer , 2021 , 157 : 190 - 197 . DOI: 10.1016/j.ejca.2021.08.030 http://doi.org/10.1016/j.ejca.2021.08.030

CORRÊA G T , BANDEIRA G A , CAVALCANTI B G , et al . Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival [J ] . Support Care Cancer , 2012 , 20 ( 11 ): 2679 - 2685 . DOI: 10.1007/s00520-012-1386-y http://doi.org/10.1007/s00520-012-1386-y

BLACK C M , WANG L Y , RAMAKRISHNAN K , et al . Real-world time on treatment analysis of pembrolizumab treated recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC) patients stratified by ECOG PS in the United States [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): e18007 .

LANGER C , VON DER HEYDE E , HAHN D A , et al . 680P HANNA: real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-line population, treated with nivolumab in Germany [J ] . Ann Oncol , 2022 , 33 : S854 .

CLINICALTRIALS GOV . Phase Ⅱ trial of pembrolizumab in recurrent or metastatic HNSCC (POPPY) [EB/OL ] . [2019-1-23 ] . https://clinicaltrials.gov/ct2/show/NCT03813836?term=POPPY & draw=5 & rank=5. https://clinicaltrials.gov/ct2/show/NCT03813836?term=POPPY&draw=5&rank=5 https://clinicaltrials.gov/ct2/show/NCT03813836?term=POPPY&draw=5&rank=5

THERASSE P , ARBUCK S G , EISENHAUER E A , et al . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [J ] . J Natl Cancer Inst , 2000 , 92 ( 3 ): 205 - 216 . DOI: 10.1093/jnci/92.3.205 http://doi.org/10.1093/jnci/92.3.205

NISHINO M . Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment [J ] . J Immunother Cancer , 2016 , 4 : 30 .

SEYMOUR L , BOGAERTS J , PERRONE A , et al . iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [J ] . Lancet Oncol , 2017 , 18 ( 3 ): e143 - e152 . DOI: 10.1016/S1470-2045(17)30074-8 http://doi.org/10.1016/S1470-2045(17)30074-8

PARK J H , CHUN S H , LEE Y G , et al . Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12 [J ] . J Cancer Res Clin Oncol , 2020 , 146 ( 12 ): 3359 - 3369 .

ZHANG H C , FANG X F , LI D , et al . Hyperprogressive disease in patients receiving immune checkpoint inhibitors [J ] . Curr Probl Cancer , 2021 , 45 ( 3 ): 100688 .

SAÂDA-BOUZID E , DEFAUCHEUX C , KARABAJAKIAN A , et al . Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma [J ] . Ann Oncol , 2017 , 28 ( 7 ): 1605 - 1611 .

ECONOMOPOULOU P , ANASTASIOU M , PAPAXOINIS G , et al . Patterns of response to immune checkpoint inhibitors in association with genomic and clinical features in patients with head and neck squamous cell carcinoma (HNSCC) [J ] . Cancers , 2021 , 13 ( 2 ): 286 .

KARABAJAKIAN A , GARRIVIER T , CROZES C , et al . Addendum: hyperprogression and impact of tumor growth kinetics after PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma [J ] . Oncotarget , 2022 , 13 : 1305 .

KANG Y K , RECK M , NGHIEM P , et al . Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase Ⅲ, randomized, controlled trials [J ] . J Immunother Cancer , 2022 , 10 ( 4 ): e004273 .

CHAMPIAT S , DERCLE L , AMMARI S , et al . Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 [J ] . Clin Cancer Res , 2017 , 23 ( 8 ): 1920 - 1928 . DOI: 10.1158/1078-0432.CCR-16-1741 http://doi.org/10.1158/1078-0432.CCR-16-1741

REFAE S , GAL J , BREST P , et al . Hyperprogression under immune checkpoint inhibitor: a potential role for germinal immunogenetics [J ] . Sci Rep , 2020 , 10 ( 1 ): 3565 . DOI: 10.1038/s41598-020-60437-0 http://doi.org/10.1038/s41598-020-60437-0

KATO S , GOODMAN A , WALAVALKAR V , et al . Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate [J ] . Clin Cancer Res , 2017 , 23 ( 15 ): 4242 - 4250 . DOI: 10.1158/1078-0432.CCR-16-3133 http://doi.org/10.1158/1078-0432.CCR-16-3133

BURTNESS B , HARRINGTON K , GREIL R , et al . LBA8_PRKEYNOTE-048: phase Ⅲ study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) [J ] . Ann Oncol , 2018 , 29 ( suppl_8 ): Ⅷ729 .

中国临床肿瘤学会指南工作委员会组织 . 中国临床肿瘤学会(CSCO)免疫检查点抑制剂临床应用指南-2021 [M ] . 北京 : 人民卫生出版社 , 2021 .

Organized by the Guidelines Working Committee of the Chinese Society of Clinical Oncology . Chinese Society of Clinical Oncology (CSCO) clinical application guidelines for immune checkpoint inhibitors-2021 [M ] . Beijing : People's Health Publishing House , 2021 .

National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN guidelines) for management of immunotherapy-related toxicities.Version1.2022 [EB/OL ] . [2022-2-28 ] . https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf

WISE-DRAPER T M , GULATI S , PALACKDHARRY S , et al . Phase Ⅱ clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma [J ] . Clin Cancer Res , 2022 , 28 ( 7 ): 1345 - 1352 .

UPPALURI R , CAMPBELL K M , EGLOFF A M , et al . Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase Ⅱ trial [J ] . Clin Cancer Res , 2020 , 26 ( 19 ): 5140 - 5152 .

UPPALURI R , CHERNOCK R , MANSOUR M , et al . Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC) [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): 6008 .

FERRIS R L , SPANOS W C , LEIDNER R , et al . Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial [J ] . J Immunother Cancer , 2021 , 9 ( 6 ): e002568 .

ZINNER R , JOHNSON J M , TULUC M , et al . Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer [J ] . J Clin Oncol , 2020 , 38 ( 15_suppl ): 6583 .

UPPALURI R , LEE N , WESTRA W , et al . KEYNOTE-689: phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma [J ] . J Clin Oncol , 2019 , 37 ( 15_suppl ): TPS6090 .

Views

2195

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Survival impact of corticosteroid and immunosuppressant management strategies for immune-related adverse events in immune checkpoint inhibitor-treated patients: a systematic review and meta-analysis

Expert consensus on BRCA1/2 gene testing and clinical application in Chinese breast cancer patients (2025 edition)

Chinese expert consensus on whole-process management of chemotherapy-related diarrhea (2025 edition)

Expert consensus on the combination of anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma (2025 edition)

Research progress on treatment of pleural effusion related to immune checkpoint inhibitors

Related Author

Dongqin CHEN

Yicheng ZHOU

Xinyue LAN

Hongxia WANG

Yongmei YIN

Xichun HU

Association Committee of Rehabilitation and Palliative Care China Anti-Cancer

Association Committee of Cancer Pain Fujian Anti-Cancer

Related Institution

Department of Medical Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine

Committee of Breast Cancer Society, Chinese Anti-Cancer Association; Clinical Precision Medicine Professional Committee, Chinese Medical Doctor Association; Tumor Heterogeneity and Personalized Therapy Professional Committee, Chinese Anti-Cancer Association

Committee of Head and Neck Cancer, Chinese Society of Clinical Oncology

Clinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Institute of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine

Department of Oncology, The First Affiliated Hospital of Zhengzhou University

AI问答

⁰